Cargando…

103. Persistence on F/TDF for HIV Pre-exposure Prophylaxis: Insights from Real-world Evidence

BACKGROUND: Background: Daily F/TDF is highly effective for HIV pre-exposure prophylaxis (PrEP). Prior studies have found that women and people of younger age have lower adherence and lower persistence on PrEP, yet real-world evidence describing persistence associated with other clinical characteris...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tao, Li, Shvachko, Valentina, Mera, Robertino, Das, Moupali, Carter, Christoph, Magnuson, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777742/ http://dx.doi.org/10.1093/ofid/ofaa439.413

Ejemplares similares

855. Persistence on F/TAF versus F/TDF for HIV Pre-Exposure Prophylaxis: A Real-World Evidence Analysis in the United States
por: Tao, Li, et al.
Publicado: (2021)

995. Safety and Efficacy of F/TAF and F/TDF for PrEP in DISCOVER Participants Taking F/TDF for PrEP at Baseline
por: Campbell, Thomas, et al.
Publicado: (2020)

1556. Increase in New HIV Diagnoses Following Decrease in Use of Pre-Exposure Prophylaxis (PrEP) During the COVID-19 Pandemic
por: Tao, Li, et al.
Publicado: (2023)

866. Adherence to F/TDF for PrEP in Dried Blood Spots and HIV Infection Rates: A Pooled Analysis of Global PrEP Studies
por: Liu, Albert, et al.
Publicado: (2021)

Two years of Truvada for pre-exposure prophylaxis utilization in the US
por: Flash, Charlene, et al.
Publicado: (2014)

1288. Bone Safety Outcomes with F/TAF vs. F/TDF for PrEP in the DISCOVER Trial
por: Wohl, David, et al.
Publicado: (2019)

1962. Renal Outcomes for Participants Taking F/TAF vs. F/TDF for HIV PrEP in the DISCOVER Trial
por: Mills, Anthony, et al.
Publicado: (2019)

2088. Real-World Geographic Variations of HIV Diagnosis Rates among Individuals Prescribed and not Prescribed Oral HIV Pre-Exposure Prophylaxis (PrEP) Regimens in the United States
por: Tao, Li, et al.
Publicado: (2022)

1963. PrEP Significantly Reduces the Rate of New HIV Diagnoses in US Metropolitan Statistical Areas Independent of Treatment as Prevention (2012–2017)
por: Mera-Giler, Robertino M, et al.
Publicado: (2019)

Estimation of new HIV diagnosis rates among high‐risk, PrEP‐eligible individuals using HIV surveillance data at the Metropolitan Statistical Area level in the United States
por: Mera, Robertino, et al.
Publicado: (2019)

999. Using the F/TDF Adherence-Efficacy Relationship to Calculate Background HIV incidence: Results from the DISCOVER trial
por: Glidden, David V, et al.
Publicado: (2020)

Long-term efficacy and safety of E/C/F/TDF vs EFV/FTC/TDF and ATV+RTV+FTC/TDF in HIV-1-infected treatment-naïve subjects ≥50 years
por: Gazzard, Brian, et al.
Publicado: (2014)

853. Real-World Persistency of Patients Receiving Tenofovir-Based Pre-Exposure Prophylaxis for the Prevention of HIV Infection in the US
por: Oglesby, Alan, et al.
Publicado: (2021)

Efficacy and Safety of Oral TDF-Based Pre-exposure Prophylaxis for Men Who Have Sex With Men: A Systematic Review and Meta-Analysis
por: Huang, Xiaojie, et al.
Publicado: (2018)

Depression and Oral FTC/TDF Pre-exposure Prophylaxis (PrEP) Among Men and Transgender Women Who Have Sex With Men (MSM/TGW)
por: Defechereux, Patricia A., et al.
Publicado: (2015)

Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients With Virological Suppression: A Randomized Controlled Trial
por: Wiriyatanakorn, Sirichai, et al.
Publicado: (2019)

TDF (Theoretical Domain Framework): how inclusive are TDF domains and constructs compared to other tools for assessing barriers to change?
por: Sarmast, Hamideh, et al.
Publicado: (2014)

318. Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF) in Hispanic/Latinx and Black Participants: Efficacy, Bone and Renal Safety Results from a Pooled Analysis of 7 Clinical Trials
por: DeJesus, Edwin, et al.
Publicado: (2019)

Antithrombotic prophylaxis of atrial fibrillation in an Italian real-world setting: a retrospective study
por: Ermini, Giuliano, et al.
Publicado: (2017)

Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP)
por: Cespedes, Michelle, et al.
Publicado: (2022)

Pre-Existing Frailty is Unrelated to Progression of Diffuse Subcortical Damage of Vascular Origin: A Longitudinal Prospective Study in Community-Dwelling Older Adults
por: Del Brutto, Oscar H., et al.
Publicado: (2022)

Naïve patients receiving TDF/FTC-EFV as 2 pills are more likely to modify regimen components than patients receiving a TDF/FTC/EFV single pill
por: Perez-Valero, I, et al.
Publicado: (2010)

Switching at Low HIV-1 RNA into Fixed Dose Combinations: TDF/FTC/RPV is non-inferior to TDF/FTC/EFV in first-line suppressed patients living with HIV
por: Munderi, Paula, et al.
Publicado: (2019)

Lipidomics Reveals Reduced Inflammatory Lipid Species and Storage Lipids after Switching from EFV/FTC/TDF to RPV/FTC/TDF: A Randomized Open-Label Trial
por: Curran, Adrian, et al.
Publicado: (2020)

Risk-Taking Behaviors and Adherence to HIV Pre-Exposure Prophylaxis in Users of Geosocial Networking Apps: Real-World, Multicenter Study
por: Wang, Hongyi, et al.
Publicado: (2020)

Oral HIV pre-exposure prophylaxis use among pregnant and postpartum women: results from real-world implementation in Lesotho
por: Masenyetse, Lieketseng J., et al.
Publicado: (2023)

Factors Associated With a Persistent Seronegative Status 1 Year After a SARS-CoV-2 Massive Infection Outbreak in Community Dwellers Living in Rural Ecuador: A Prospective Population-based Study
por: Del Brutto, Oscar H., et al.
Publicado: (2021)

Persistence of Eosinophilic Asthma Endotype and Clinical Outcomes: A Real-World Observational Study
por: Tran, Trung N, et al.
Publicado: (2021)

Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials
por: Hagins, D, et al.
Publicado: (2018)

Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection
por: Bekerman, Elena, et al.
Publicado: (2020)

337. Switching from TDF to TAF: Missed Opportunities for Statin Use in HIV
por: Mallon, Patrick, et al.
Publicado: (2019)

TdfH selectively binds metal-loaded tetrameric calprotectin for zinc import
por: Bera, Aloke K., et al.
Publicado: (2022)

Correction: Risk-Taking Behaviors and Adherence to HIV Pre-Exposure Prophylaxis in Users of Geosocial Networking Apps: Real-World, Multicenter Study
por: Wang, Hongyi, et al.
Publicado: (2020)

1557. The Real-World Impact of Pre-Exposure Prophylaxis (PrEP) Prescription Uptake and Dispensing Status on HIV Infection Risk in the US
por: Tao, Li, et al.
Publicado: (2023)

1560. Factors Driving Decisions in the use of HIV Pre-Exposure Prophylaxis: Data from a Real-World Study in the United States
por: Whiteside, Yohance, et al.
Publicado: (2023)

Symphony No. 103/
por: Haydn, Joseph

Real-world Evidence for Adherence and Persistence with Atorvastatin Therapy
por: Tsioufis, Konstantinos, et al.
Publicado: (2021)

Primary Prophylaxis Lapelga(®) in Early Breast Cancer: A Real-World Experience
por: Khan, Fahad, et al.
Publicado: (2023)

Real‐world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real‐world study
por: Gladstone, Jonathan, et al.
Publicado: (2021)

1298. Acquisition of TDF-Susceptible HIV Despite High Level Adherence to Daily TDF/FTC PrEP as Measured by Dried Blood Spot (DBS) and Segmental Hair Analysis: A Case Report
por: Cohen, Stephanie E, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_743curegpebaapa7ibr5ga4vma